Financial Consulate’s Ligand Pharmaceuticals LGND Stock Holding History

Financial Consulate’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$313	Buy	+1	New	+$296	﹤0.01%	1572

Other funds holding LGND

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.32B AUM 31.14% 1-Year Est. Return

Pembroke Management Montreal, Quebec, Canada $809M AUM 17.64% 1-Year Est. Return

Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Moran Wealth Management Naples, Florida $3.64B AUM 28.63% 1-Year Est. Return

Woodstock Corp Boston, Massachusetts $1.24B AUM 22.02% 1-Year Est. Return

Isthmus Partners Madison, Wisconsin $1.04B AUM 19.97% 1-Year Est. Return

Moody National Bank Trust Division Galveston, Texas $1.21B AUM 28.25% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Financial Consulate's LGND Position: Q3 2026 in Review

Financial Consulate opened a new position in Ligand Pharmaceuticals (LGND) in Q3 2026: 1 share worth $313. The stake represents ﹤0.01% of the portfolio and ranks #1572 among its holdings.

82 funds tracked by Wall St. Rank hold LGND as of Q3 2026.

Financial Consulate held 1 share of Ligand Pharmaceuticals worth $313 as of Q3 2026.
Ligand Pharmaceuticals was a new Financial Consulate position in Q3 2026.
Ligand Pharmaceuticals made up ﹤0.01% of Financial Consulate's portfolio in Q3 2026, its #1572 holding.
82 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2026.

Based on Financial Consulate's 13F filing for Q3 2026, filed 23 Oct 2026.